Cargando…
Adjuvant Ipilimumab in High-Risk Uveal Melanoma
Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in...
Autores principales: | Fountain, Eric, Bassett, Roland L., Cain, Suzanne, Posada, Liberty, Gombos, Dan S., Hwu, Patrick, Bedikian, Agop, Patel, Sapna P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406862/ https://www.ncbi.nlm.nih.gov/pubmed/30699934 http://dx.doi.org/10.3390/cancers11020152 |
Ejemplares similares
-
Metastasis of Ciliary Body Melanoma to the Contralateral Eye: A Case Report and Review of Uveal Melanoma Literature
por: Torossian, Nouritza M., et al.
Publicado: (2015) -
Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
por: Khimani, Karima, et al.
Publicado: (2022) -
Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients
por: Ballhausen, Alexej, et al.
Publicado: (2021) -
Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma
por: Anand, Kartik, et al.
Publicado: (2019) -
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
por: Qin, Yong, et al.
Publicado: (2020)